These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 7585113)

  • 1. Rational drug design and HIV: hopes and limitations.
    Goody RS
    Nat Med; 1995 Jun; 1(6):519-20. PubMed ID: 7585113
    [No Abstract]   [Full Text] [Related]  

  • 2. Structural mechanisms of HIV drug resistance.
    Erickson JW; Burt SK
    Annu Rev Pharmacol Toxicol; 1996; 36():545-71. PubMed ID: 8725401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Closing in on human immunodeficiency virus-1.
    Mellors JW
    Nat Med; 1996 Mar; 2(3):274-5. PubMed ID: 8612219
    [No Abstract]   [Full Text] [Related]  

  • 4. Harnessing nature's insight: design of aspartyl protease inhibitors from treatment of drug-resistant HIV to Alzheimer's disease.
    Ghosh AK
    J Med Chem; 2009 Apr; 52(8):2163-76. PubMed ID: 19323561
    [No Abstract]   [Full Text] [Related]  

  • 5. New wave antiretrovirals.
    Smart T
    GMHC Treat Issues; 1996 Sep; 10(9):1-3. PubMed ID: 11363838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and experience with reverse transcriptase inhibitors and protease inhibitors.
    Vella S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S58-61. PubMed ID: 8595511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of HIV proteinase.
    Martin JA; Redshaw S; Thomas GJ
    Prog Med Chem; 1995; 32():239-87. PubMed ID: 8577919
    [No Abstract]   [Full Text] [Related]  

  • 8. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase.
    Wainberg MA; Drosopoulos WC; Salomon H; Hsu M; Borkow G; Parniak M; Gu Z; Song Q; Manne J; Islam S; Castriota G; Prasad VR
    Science; 1996 Mar; 271(5253):1282-5. PubMed ID: 8638110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development.
    de Clercq E
    Med Res Rev; 1996 Mar; 16(2):125-57. PubMed ID: 8656777
    [No Abstract]   [Full Text] [Related]  

  • 10. Therapeutic approaches to HIV infection based on virus structure and the host pathogen interaction.
    Pauza CD; Streblow DN
    Curr Top Microbiol Immunol; 1995; 202():117-32. PubMed ID: 7587359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interview with Celia Schiffer.
    Schiffer C
    Future Med Chem; 2013 Jul; 5(11):1193-7. PubMed ID: 23859201
    [No Abstract]   [Full Text] [Related]  

  • 12. Antiretroviral agents as inhibitors of both human immunodeficiency virus type 1 integrase and protease.
    Mazumder A; Wang S; Neamati N; Nicklaus M; Sunder S; Chen J; Milne GW; Rice WG; Burke TR; Pommier Y
    J Med Chem; 1996 Jun; 39(13):2472-81. PubMed ID: 8691444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How to overcome resistance of HIV-1 to HIV-1-specific reverse transcriptase inhibitors.
    De Clercq E
    AIDS; 1994 Jul; 8(7):1020-1. PubMed ID: 7524543
    [No Abstract]   [Full Text] [Related]  

  • 14. Rational design of polymerase inhibitors as antiviral drugs.
    Oberg B
    Antiviral Res; 2006 Sep; 71(2-3):90-5. PubMed ID: 16820225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highlights of the Fourth International Workshop on HIV Drug Resistance.
    Lange JM; deJong MD
    J Int Assoc Physicians AIDS Care; 1995 Aug; 1(7):25-7. PubMed ID: 11362748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conference looks at HIV drug resistance.
    Chang HE
    GMHC Treat Issues; 1995 Sep; 9(9):6-8. PubMed ID: 11362910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of inhibitors of reverse transcriptase and protease as therapeutics against HIV infection.
    Mitsuya H
    J Enzyme Inhib; 1992; 6(1):1-8. PubMed ID: 1285300
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacologic therapy for human immunodeficiency virus infection: a review.
    Neuzil KM
    Am J Med Sci; 1994 May; 307(5):368-73. PubMed ID: 7513499
    [No Abstract]   [Full Text] [Related]  

  • 19. Qualitative study of drug resistance in retroviral protease using structural modeling and site-directed mutagenesis.
    Culberson JC; Bush BL; Sardana VV
    Methods Enzymol; 1994; 241():385-94. PubMed ID: 7854190
    [No Abstract]   [Full Text] [Related]  

  • 20. An interview with Charles A.B. Boucher, MD, PhD. Interview by Mark Mascolini.
    Boucher CA
    J Int Assoc Physicians AIDS Care; 1995 Nov; 1(10):30-5. PubMed ID: 11362972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.